High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland. Lead author Dr Manon Evans, research fellow at the Christie Hospital in Manchester, UK, said: “Despite the wide and increasing range of therapies available, the management of metastatic renal cell carcinoma (mRCC) remains challenging. Agents targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways are currently the standard of care. Whilst these therapies are well tolerated and demonstrate impressive response rates, the responses seen are very rarely complete and durable.”

READ FULL ARTICLE Curated publisher From Medical News Today